Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Nets $41M in Financing for IVD Development, Launch

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

The company plans to use the new capital to validate its Idylla platform and to continue developing a range of assays, most of them oncology-related.

Biocartis plans to launch the Idylla, a scalable biomarker-based in vitro diagnostic platform that does not require a lab environment or trained technicians, and its BRAF cancer assay, in the second half of 2014.

The investors in this financing round include existing shareholders such as RMM; Debiopharm Diagnostics; PMV Tina Fund; Johnson and Johnson Development Corporation; Philips; the Wellcome Trust; Petercam; Paul Janssen; Luc Verelst; Biocartis Founder Rudi Pauwels; and some smaller shareholders and company employees.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.